News Orexo exits depression DTx alliance with GAIA Four years after buying US rights to GAIA's digital therapeutic to help people with depression, Swedish drugmaker Orexo has terminated the deal.
News Orexo buys US rights to GAIA's deprexis digital therapeutic Sweden's Orexo has announced it has bought the exclusive US rights to GAIA’s deprexis, a digital therapy to help patients manage their symptoms of depression and one of the most researched
R&D Modelling biologics: Challenges and opportunities, with Dr D... From AAPS 2025, an interview with Dr Dhaval Shah, professor of pharmaceutical sciences at the University of Buffalo and former Pfizer researcher.
Market Access Sponsored Bridging research and clinical guidelines – interactive stra... Medical affairs is evolving. Understanding how to harness real-world data and digital insights is essential.
